Methods and compositions are provided for prophylaxis and treatment of
breast cancer involving administration of a therapeutically effective amount of
carbetocin and / or other long-acting
oxytocin analogues. 1-Butanoic acid-2-(O-methyl-L-
tyrosine)-1-carbaoxytocin (
carbetocin) and / or other long-acting
oxytocin analogues are formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to inhibit
initiation or growth of
breast cancer in the patient. The
carbetocin and / or other long-acting
oxytocin analogues may also be formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to treat, prevent or alleviate the symptoms of a psychiatric disorder in the patient.
Carbetocin may be administered prophylactically or to treat existing conditions in patients by a variety of administration
modes, including intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal
delivery methods and formulations. Preferably, the carbetocin is administered to a mucosal surface of the patient via intranasal delivery. For this purpose, pharmaceutical compositions are provided for intranasal delivery that incorporate carbetocin in a
powder or aqueous formulation for intranasal delivery.